Background Endovascular thrombectomy (EVT) has become the mainstay treatment for large vessel occlusion, with favorable safety and efficacy profile. However, the safety and efficacy of EVT in concurrent multi-territory occlusions (MTVOs) remains unclear.
Objective To investigate the prevalence, clinical and technical outcomes of concurrent EVT for MTVOs.
Methods Data were included from the Stroke Thrombectomy and Aneurysm Registry (STAR) with 32 stroke centers for EVT performed to treat bilateral anterior or concurrent anterior and posterior circulation occlusions between 2017 and 2021. Patients with MTVO were identified, and propensity score matching was used to compare this group with patients with occlusion in a single arterial territory.
Results Of a total of 7723 patients who underwent EVT for acute ischemic stroke, 54 (0.7%) underwent EVT for MTVOs (mean age 69±12.5; female 50%). 28% had bilateral and 72% had anterior and posterior circulations occlusions. The rate of successful recanalization (Thrombolysis in Cerebral Infarction 2b/3), complications, modified Rankin score at 90 days, and mortality was not significantly different between the matched cohorts. Multivariate analysis confirmed that MTVOs were not associated with poor functional outcome, symptomatic intracranial hemorrhage, or longer procedure time.
Conclusion Compared with EVT for single vessel occlusions, EVT in appropriately selected patients with MTVOs has a similar efficacy and safety profile.
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @BrianHoward_MD, @PascalJabbourMD, @Starke_neurosurgery, @AdamArthurMD, @DrMichaelLevitt
Contributors Conception or design of the work: HS, SE, AA, CMC, BMH, AS, JAG. Data collection: all authors. Data analysis and interpretation: HS, SE, AA, JAG. Drafting the article: HS, SE, AA, JAG. Critical revision of the article: all authors. Final approval of the version to be published: all authors. JAG: Guarantor for the work and the conduct of the study.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SAK: Grant funding-Stryker. PJ: Consultant - Balt, Cerus, Microvention, Medtronic. SQW: Board of directors - AANS; associate editor - S:VIN journal. M-NP: Honoraria - Stryker, Medtronic, Penumbra, Acandis, Phenox, Siemens Healthineers; research support - Swiss National Science Foundation, Bangerter-Rhyner Stiftung, Stryker, Phenox, Medtronic, Rapid, Penumbra, Siemens Healthineers. ASA: Consultant for Arsenal, Balt, Johnson and Johnson, Medtronic, Microvention, Penumbra, Scientia, Siemens, Stryker; research support from Balt, Medtronic, Microvention, Penumbra, and Siemens; shareholder - Azimuth, Bendit, Cerebrotech, Endostream, Magneto, Mentice, Neurogami, Neuros, Scientia, Serenity, Synchron, Tulavi, Vastrax, VizAI. AJP: Consultant - Depuy Synthes, Stryker. JM: consultant - Stryker. CM: Consultant-Silk Road, Penumbra, Microvention, Cerevasc, Stryker; speaker-Silk Road, Penumbra. MSP: DSMB-Medtronic. MRL: Educational grant - Stryker, Medtronic; consultant - Medtronic, Aeaean Advisers; travel Support - Penumbra; editorial board, JNIS; stock - Hyperion Surgical, Proprio, Synchron, Cerebrotech, Fluid Biomed, Stereotaxis; advisor - Metis Innovative. AMS: Consultant - Stryker, Penumbra, Terumo, RapidAI. JAG: Grant support- Georgia Research Alliance, Department of Defense, Emory Medical Care Foundation, Neurosurgery Catalyst; Stock - NTI, Cognition. STAR: funded by Penumbra, Medtronic, Stryker.
Provenance and peer review Not commissioned; externally peer reviewed.